Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452092 | 1.00 | HRH1 (0.50) | HRH1HTR2ALOXL2CYP2A6SMN1; SMN2 | |
| SCHEMBL27706642 | 0.87 | ADRB2 (0.60) | LOXL2CYP2A6SMN1; SMN2TAAR1CA12 | |
| SCHEMBL30083578 | 0.85 | ADRB2 (0.62) | LOXL2CYP2A6SMN1; SMN2TAAR1CA12 | |
| SCHEMBL505581 | 0.85 | ADRB2 (0.62) | LOXL2CYP2A6SMN1; SMN2TAAR1CA12 | |
| SCHEMBL2344310 | 0.84 | CYP1A2 (0.58) | CYP2A6SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL14268241 | 0.83 | BRS3 (0.50) | CYP2A6SMN1; SMN2CA12CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL3722160 | 0.83 | ADRB2 (0.60) | LOXL2CYP2A6SMN1; SMN2TAAR1CA12 | |
| Hydrochloric Acid SCHEMBL31682452 | 0.83 | ADRB2 (0.60) | LOXL2CYP2A6SMN1; SMN2TAAR1CA12 | |
| SCHEMBL1138773 | 0.81 | HCAR2 (0.50) | CYP2A6CA12CA1CA2CA9 | |
| SCHEMBL1129824 | 0.81 | CYP1A2 (0.47) | CYP2A6SMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814355-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| CN-111164084-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20210292334-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-09-23 | — | — | US | disclosed |
| US-20210292334-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-09-23 | — | — | US | disclosed |
| EP-3814355-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2021-05-05 | — | — | EP | disclosed |
| CN-111164084-A | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| US-7056937-B2 | Sulfonylquinoxalone derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | HRH1 393/4885HTR2A 7/4885LOXL2 2975/4885 |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | BDKRB2, BDKRB1, HRH2 | HRH1 34/4885HTR2A 871/4885LOXL2 1757/4885 |
| US-20210292334-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | HRH1 393/4885HTR2A 7/4885LOXL2 2975/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | HRH1 1787/4885HTR2A 4438/4885LOXL2 1139/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | HRH1 3952/4885HTR2A 3651/4885LOXL2 2596/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | HRH1 1753/4885HTR2A 4432/4885LOXL2 1181/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | HRH1 34/4885HTR2A 888/4885LOXL2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.